drugset / Trial / NCT05360238
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Non-randomizedSequentialOpen-labelTreatment
Summary
Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL
Timeline
- Start
- 2022-05-24
- Primary completion
- 2024-04-12
- Completion
- 2024-04-12
Outcome
Outcome not reported
Stopped (Business): “Business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MB-106 | Cell therapy | 3.3e+07 cells/kg | Intravenous |